Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons R.A. (Rudolf) de Boer

Publicaties

An increase in albuminuria is associated with a higher incidence of malignancies

Association of fibrotic markers with diastolic function after STEMI

Associations of relative fat mass and BMI with all-cause mortality: Confounding effect of muscle mass

Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology

Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial

Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial

Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER

Deletion of DWORF does not affect cardiac function in ageing and in PLN-R14del cardiomyopathy

Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD): a multicentre, pragmatic, cluster-randomised, controlled trial

Early consequences of the phospholamban mutation PLN-R14del+/− in a transgenic mouse model

Lees meer

Pers/media

ESC-congres 2023 Gesprek van de dag | Hartfalen

FOCUS: praktische overwegingen bij starten van SGLT2-remmers bij hartfalen

De nieuwe ESC-hartfalenrichtlijn 2021 in het kort

Eerste kunsthart in Nederland geplaatst bij 54-jarige man

Dr Rudolf de Boer on SGLT2 Inhibitor Success Across Disease States

Nier- en HF-uitkomsten met SGLT2-remmer in het gehele EF spectrum in HF

Dr Rudolf de Boer Discusses Encouraging Trial Results on SGLT2 Use in HFpEF

Effecten van SGLT2-remmers in vogelvlucht

Margreet Westerhof heeft de noordelijke hartziekte PLN: 'Je leeft met een tijdbom'

Lees meer